0000950142-12-000415.txt : 20120215
0000950142-12-000415.hdr.sgml : 20120215
20120215191552
ACCESSION NUMBER: 0000950142-12-000415
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120213
FILED AS OF DATE: 20120215
DATE AS OF CHANGE: 20120215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ELMS STEVE
CENTRAL INDEX KEY: 0001250195
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-52120
FILM NUMBER: 12617277
MAIL ADDRESS:
STREET 1: 888 SEVENTH AVE
STREET 2: 29TH FL
CITY: NEW YORK
STATE: NY
ZIP: 10106
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: R&R ACQUISITION VI, INC
CENTRAL INDEX KEY: 0001368514
STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770]
IRS NUMBER: 562590042
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 1270 AVENUE OF THE AMERICAS
STREET 2: 16TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10020
BUSINESS PHONE: 973-635-4047
MAIL ADDRESS:
STREET 1: 1270 AVENUE OF THE AMERICAS
STREET 2: 16TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10020
4
1
es1200317_4-elms.xml
OWNERSHIP DOCUMENT
X0304
4
2012-02-13
0
0001368514
R&R ACQUISITION VI, INC
NONE
0001250195
ELMS STEVE
888 SEVENTH AVE
30TH FL
NEW YORK
NY
10106
1
0
0
0
Common Stock
2012-02-13
4
A
0
2516855
A
2516855
I
See Footnote
On February 13, 2012, the issuer's wholly-owned subsidiary merged with ADMA Biologics, Inc., a privately-held Delaware corporation ("Former ADMA"). The issuer changed its name to ADMA Biologics, Inc. In connection with the merger and pursuant to the terms of the merger agreement, holders of Former ADMA's common stock received shares of the issuer's common stock and holders of options to purchase Former ADMA's common stock received options to purchase the same number of the issuer's common stock at the same exercise price. The reporting person indirectly acquired the issuer's securities in exchange for securities of Former ADMA. The issuer's shares of common stock are not currently listed on an exchange or quoted on the OTC Bulletin Board.
The reportable securities are owned directly by Aisling Capital II, LP ("Aisling"), and held indirectly by Aisling Capital Partners, LP ("Aisling GP"), as general partner of Aisling, and Aisling Capital Partners, LLC ("Aisling Partners"), as general partner of Aisling GP. Mr. Elms is a managing member of Aisling and is a member of the Board of Directors of ADMA Biologics, Inc. Mr. Elms disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
/s/ Steve Elms
2012-02-15